Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination

Urology

Volumn 57, Issue 1, 2001, Pages 83-90

  Schröder, Fritz H ^a   Roobol Bouts, Monique ^a   Vis, André N ^a   Van der Kwast, Theo ^a   Kranse, Ries ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TRANSRECTAL ULTRASONOGRAPHY;

AGED; BIOPSY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PALPATION; PHYSICAL EXAMINATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES;

EID: 0035148435     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00863-3     Document Type: Article

References (19)

1. Advanced prostate cancer; course, care, and cost implications
2. Serum prostate specific antigen as pre-screening test for prostate cancer
3. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml prostate specific antigen
4. Digital rectal examination (DRE)-its value in the diagnosis of prostate cancer
5. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region)
6. Prospective evaluation plan for randomised trials of prostate cancer screening
7. European randomized study of screening for prostate cancer-the Rotterdam pilot studies
8. Rationale for randomised trials of prostate cancer screening; review
9. Making the most out of sextant biopsy
10. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate
11. Comparison of pathological characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer
12. Prostate cancer detection at low values of prostate specific antigen
13. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
14. The pathological features and prognosis of prostate cancers detectable with current diagnostic tests
15. The nature of prostate cancer detected through prostate specific antigen based screening
16. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based on screening
17. Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng/ml or less
18. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination
19. PSA testing and use of DRE before and during a randomised trial of screening for prostate cancer (ERSPC, Rotterdam)